NasdaqGS - Nasdaq Real Time Price • USD
Pacific Biosciences of California, Inc. (PACB)
As of 11:59 AM EDT. Market Open.
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 13 | 12 | 14 | 14 |
Avg. Estimate | -0.27 | -0.25 | -1.02 | -0.82 |
Low Estimate | -0.32 | -0.29 | -1.11 | -0.99 |
High Estimate | -0.23 | -0.22 | -0.89 | -0.52 |
Year Ago EPS | -0.36 | -0.28 | -1.21 | -1.02 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 11 | 10 | 14 | 14 |
Avg. Estimate | 42.96M | 46.63M | 204.67M | 288.16M |
Low Estimate | 38.75M | 41.24M | 171.8M | 224.97M |
High Estimate | 51.4M | 58.2M | 240.4M | 386.5M |
Year Ago Sales | 34.38M | -- | 200.52M | 204.67M |
Sales Growth (year/est) | 25.00% | -- | 2.10% | 40.80% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.33 | -0.32 | -0.33 | -0.28 |
EPS Actual | -0.36 | -0.28 | -0.26 | -0.31 |
Difference | -0.03 | 0.04 | 0.07 | -0.03 |
Surprise % | -9.10% | 12.50% | 21.20% | -10.70% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.27 | -0.25 | -1.02 | -0.82 |
7 Days Ago | -0.28 | -0.26 | -1.03 | -0.84 |
30 Days Ago | -0.27 | -0.26 | -1.03 | -0.85 |
60 Days Ago | -0.27 | -0.26 | -1.03 | -0.84 |
90 Days Ago | -0.27 | -0.25 | -1.01 | -0.76 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | 1 | 1 | 1 |
Up Last 30 Days | 4 | 6 | 7 | 5 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 1 | -- | 2 | 2 |
Growth Estimates
CURRENCY IN USD | PACB | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 25.00% | -- | -- | 1.50% |
Next Qtr. | 10.70% | -- | -- | 11.40% |
Current Year | 15.70% | -- | -- | 5.20% |
Next Year | 19.60% | -- | -- | 13.40% |
Next 5 Years (per annum) | -1.00% | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Downgrade | JP Morgan: Overweight to Neutral | 4/22/2024 |
Maintains | Goldman Sachs: Neutral to Neutral | 4/19/2024 |
Maintains | Bernstein: Outperform to Outperform | 4/18/2024 |
Downgrade | Goldman Sachs: Buy to Neutral | 4/18/2024 |
Maintains | Scotiabank: Sector Outperform to Sector Outperform | 4/18/2024 |
Maintains | TD Cowen: Buy to Buy | 4/17/2024 |
Related Tickers
SINT Sintx Technologies, Inc.
0.0367
-5.17%
INVO INVO Bioscience, Inc.
1.0450
-10.68%
CUTR Cutera, Inc.
1.9500
-0.51%
NNOX Nano-X Imaging Ltd.
8.94
-1.65%
SENS Senseonics Holdings, Inc.
0.4166
-3.79%
BFLY Butterfly Network, Inc.
0.7045
-0.35%
BSX Boston Scientific Corporation
73.27
+0.49%
NUWE Nuwellis, Inc.
0.2601
+3.17%
ALGN Align Technology, Inc.
300.74
-4.16%
NVCR NovoCure Limited
12.04
-2.43%